Pulmonx (NASDAQ:LUNG) CEO Sells $96,972.59 in Stock

Pulmonx Corporation (NASDAQ:LUNG) CEO Glendon French III sold 67,813 shares of the firm’s stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $1.43, for a total value of $96,972.59. Following the transaction, the chief executive officer owned 1,409,511 shares of the company’s stock, valued at $2,015,600.73. This trade represents a 4.59% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Pulmonx Stock Performance

NASDAQ:LUNG opened at $2.02 on Friday. The company has a market capitalization of $83.33 million, a PE ratio of -1.52 and a beta of 0.07. Pulmonx Corporation has a fifty-two week low of $1.31 and a fifty-two week high of $8.12. The company has a debt-to-equity ratio of 0.62, a quick ratio of 4.15 and a current ratio of 4.86. The company has a 50 day simple moving average of $1.75 and a two-hundred day simple moving average of $1.79.

Pulmonx (NASDAQ:LUNG) last posted its quarterly earnings data on Wednesday, March 4th. The company reported ($0.25) EPS for the quarter, beating analysts’ consensus estimates of ($0.39) by $0.14. Pulmonx had a negative net margin of 59.67% and a negative return on equity of 78.35%. The company had revenue of $22.60 million for the quarter, compared to analyst estimates of $21.73 million. Research analysts anticipate that Pulmonx Corporation will post -1.55 earnings per share for the current year.

Analysts Set New Price Targets

Several equities analysts have issued reports on the company. Canaccord Genuity Group dropped their price target on Pulmonx from $6.00 to $5.00 and set a “buy” rating on the stock in a research note on Thursday. Wall Street Zen raised Pulmonx from a “sell” rating to a “hold” rating in a research note on Sunday, November 16th. D. Boral Capital reissued a “buy” rating and set a $14.00 price objective on shares of Pulmonx in a report on Thursday. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Pulmonx in a research report on Thursday, January 22nd. Five analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $5.38.

Institutional Investors Weigh In On Pulmonx

Hedge funds have recently made changes to their positions in the company. ExodusPoint Capital Management LP purchased a new stake in Pulmonx in the fourth quarter worth $4,312,000. Vestal Point Capital LP purchased a new stake in shares of Pulmonx during the third quarter valued at approximately $1,345,000. Bank of America Corp DE increased its position in shares of Pulmonx by 556.6% during the second quarter. Bank of America Corp DE now owns 481,268 shares of the company’s stock valued at $1,246,000 after acquiring an additional 407,971 shares in the last quarter. GSA Capital Partners LLP raised its holdings in Pulmonx by 78.3% in the 3rd quarter. GSA Capital Partners LLP now owns 755,467 shares of the company’s stock worth $1,224,000 after acquiring an additional 331,742 shares during the last quarter. Finally, Birchview Capital LP bought a new position in Pulmonx in the 4th quarter valued at approximately $554,000. 91.04% of the stock is currently owned by institutional investors.

More Pulmonx News

Here are the key news stories impacting Pulmonx this week:

• Positive Sentiment: Pulmonx beat Q4 expectations — EPS -$0.25 vs. consensus ~- $0.39 and revenue $22.6M vs. ~$21.7M; net loss narrowed and adjusted EBITDA improved year‑over‑year, signaling operational progress. Read More.
• Positive Sentiment: Closed a five‑year senior secured credit facility with Perceptive Advisors (initial $40M draw; up to $60M total subject to milestones), which refinanced prior debt and extends maturities to 2031 — materially improves near‑term liquidity. Read More.
• Positive Sentiment: Gross margin and cost discipline improved — Q4 gross margin ~78% and operating expenses down ~11% vs. prior year quarter, supporting a clearer path toward profitability if revenue momentum returns. Read More.
• Positive Sentiment: D. Boral Capital reaffirmed a Buy rating (high target), which can attract momentum buyers given large upside vs. current levels. Read More.
• Neutral Sentiment: Management outlined a strategic restructuring and sales‑force changes on the earnings call — intended to re‑accelerate commercial growth but the near‑term impact on procedure volumes is unclear. Read More.
• Neutral Sentiment: Some analysts updated targets (Canaccord trimmed its target but kept a Buy rating) — mixed analyst activity keeps coverage but shows differing views on recovery timing. Read More.
• Negative Sentiment: 2026 revenue guidance of $90M–$92M came in below consensus (~$94M), implying slower top‑line growth and limiting near‑term upside despite margin improvements. Read More.
• Negative Sentiment: Insider selling was reported (CEO, general counsel and other officers sold shares on March 2), which can increase perceived selling pressure and weigh on sentiment. Read More.
• Negative Sentiment: The new loan carries a high effective cost (SOFR + 7.0% with 3.75% floor and a 2% PIK option) and includes warrants — helpful for liquidity but increases interest burden and potential dilution if exercised. Read More.

About Pulmonx

Pulmonx Corporation is a commercial-stage medical device company focused on bronchoscopic lung volume reduction for patients suffering from severe emphysema. The company’s flagship therapy, the Zephyr® Endobronchial Valve System, employs one-way valves delivered via a minimally invasive bronchoscopic procedure to collapse diseased portions of the lung, reducing hyperinflation and improving respiratory function. Complementing this treatment, Pulmonx offers the Chartis® Pulmonary Assessment System, which provides clinicians with quantitative measurements of collateral ventilation to aid in patient selection and optimize clinical outcomes.

The Zephyr Valve received the CE mark in Europe in 2008 and FDA approval in the United States in 2018, and it has since been adopted by leading respiratory and thoracic centers across North America and Europe.